COVID-19 Results Briefing

Global

May 13, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 globally. The model was run on May 12, 2021, with data through May 10, 2021.

The global declines in reported cases and stagnation in daily deaths are driven by peaks in several states in India and the continued declines in the rest of the Northern Hemisphere. Peaks in some Indian states have been expected due to the combination of social distancing mandates and running out of people susceptible to infection. We expect that cases in other Indian states will peak and deaths will follow 2-3 weeks later. The global trend in the next four months will be driven by three key factors. First, the pace of vaccination scale-up, which is a function of both vaccine sharing from high-income to low-income countries, and vaccine confidence. Second, the P.1 epidemic in South America, which is entering peak seasonal transmission in the southern parts of the continent, can be substantially influenced by mask use trends and implementation where needed of social distancing mandates. Third, the spread of B.1.617, which may be 60% more transmissible than ancestral variants based on the patterns observed in India, can radically alter trends. The combination of increased transmissibility and immune escape means that potentially all countries are at risk of accelerated transmission due to B.1.617 regardless of levels of natural immunity. Reports of increasing transmission in the UK and local transmission in multiple states in Mexico point to the potential for B.1.617 surges in multiple regions in the world. Strategies to manage the current phase of the epidemic remain the same: increase vaccination wherever possible, suppress transmission through mask use and social distancing mandates where it is increasing, and limit the spread of B.1.617 through travel restrictions.

Current situation

• Daily reported cases in the last week decreased to 775,500 per day on average compared to 820,500 the week before (Figure 1).

• Daily deaths, corrected for under-reporting, in the last week stayed nearly constant at 30,300 per day on average compared to 30,900 the week before (Figure 2). COVID-19 remains the number 1 cause of death globally this week (Table 1).

• The daily death rate is greater than 4 per million in 52 countries (Figure 3). Key regions where the death rate is over 4 per million include much of South America, Eastern Europe, and multiple states in India.

• We estimated that 24% of people globally have been infected as of May 10 (Figure 5).

• Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 63 countries (Figure 6).

• The infection-detection rate globally was close to 7% on May 10 (Figure 7).
• Based on the GISAID, CDC, and various national databases and our variant spread model, we estimate the current prevalence of variants of concern (Figure 8). B.1.1.7 remains dominant in Europe, the Middle East, and North America. B.1.351 is dominant in southern Africa and may be spreading in Greece. B.1.617 is likely dominant in India, but with very limited sequencing data available this is difficult to confirm. B.1.617 is also rapidly expanding in the United Kingdom. There are also multiple states in Mexico reporting community transmission of B.1.617. P.1 remains the dominant variant in South America.

Trends in drivers of transmission

• Mobility last week was 26% lower than the pre-COVID-19 baseline (Figure 10). Mobility was near baseline (within 10%) in 67 countries. Mobility was lower than 30% of baseline in 30 countries.

• As of May 10, in Facebook surveys, 66% of people self-report that they always wore a mask when leaving their home (Figure 12). Mask use was lower than 50% in 49 countries.

• There were 138 diagnostic tests per 100,000 people on May 10 (Figure 14).

• Globally, 70.3% of people say they would accept or would probably accept a vaccine for COVID-19. The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 29% in Kazakhstan to 95% in Extremadura, Spain (Figure 18).

• In our current reference scenario, we expect that 3.3 billion people will have received at least one dose of vaccine by September 1 (Figure 19).

Projections

• In our reference scenario, which represents what we think is most likely to happen, our model projects 9,177,000 cumulative deaths on September 1, 2021. This represents 2,079,000 additional deaths from May 10 to September 1 (Figure 20). Daily deaths are expected to decline steadily until September 1 but remain over 10,000 throughout this period (Figure 21).

• If universal mask coverage (95%) were attained in the next week, our model projects 494,000 fewer cumulative deaths compared to the reference scenario on September 1, 2021 (Figure 20).

• Under our worse scenario, our model projects 10,048,000 cumulative deaths on September 1, 2021, an additional 871,000 deaths compared to our reference scenario (Figure 20). Daily deaths level out at 25,000 until August and then increase sharply to over 30,000 by September 1.

• By September 1, we project that 646,200 lives will be saved by the projected vaccine rollout. This does not include lives saved through vaccination that has already been delivered.
- Daily infections in the reference scenario will decline to below 4 million by July and then remain steady through August (Figure 22). Daily infections in the worse scenario may stay above 7 million until July and then increase.

- At some point from May through September 1, 88 countries will have high or extreme stress on hospital beds. At some point from May through September 1, 141 countries will have high or extreme stress on ICU capacity.

**Model updates**

In the IHME estimation of COVID-19 infections, hospitalizations, and deaths to date, we have used officially reported COVID-19 deaths for nearly all locations. As of today, we are switching to a new approach that relies on the estimation of total mortality due to COVID-19. There are several reasons that have led us to adopt this new approach. These reasons include the fact that testing capacity varies markedly across countries and within countries over time, which means that the reported COVID-19 deaths as a proportion of all deaths due to COVID-19 also vary markedly across countries and within countries over time. In addition, in many high-income countries, deaths from COVID-19 in older individuals, especially in long-term care facilities, went unrecorded in the first few months of the pandemic. In other countries, such as Ecuador, Peru, and the Russian Federation, the discrepancy between reported deaths and analyses of death rates compared to expected death rates, sometimes referred to as “excess mortality,” suggests that the total COVID-19 death rate is many multiples larger than official reports. Estimating the total COVID-19 death rate is important both for modeling the transmission dynamics of the disease to make better forecasts, and also for understanding the drivers of larger and smaller epidemics across different countries.

Our approach to estimating the total COVID-19 death rate is based on measurement of the excess death rate during the pandemic week by week compared to what would have been expected based on past trends and seasonality. However, the excess death rate does not equal the total COVID-19 death rate. Excess mortality is influenced by six drivers of all-cause mortality that relate to the pandemic and the social distancing mandates that came with the pandemic. These six drivers are: a) the total COVID-19 death rate, that is, all deaths directly related to COVID-19 infection; b) the increase in mortality due to needed health care being delayed or deferred during the pandemic; c) the increase in mortality due to increases in mental health disorders including depression, increased alcohol use, and increased opioid use; d) the reduction in mortality due to decreases in injuries because of general reductions in mobility associated with social distancing mandates; e) the reductions in mortality due to reduced transmission of other viruses, most notably influenza, respiratory syncytial virus, and measles; and f) the reductions in mortality due to some chronic conditions, such as cardiovascular disease and chronic respiratory disease, that occur when frail individuals who would have died from these conditions died earlier from COVID-19 instead. To correctly estimate the total COVID-19 mortality, we need to take into account all six of these drivers of change in mortality that have happened since the onset of the pandemic.
Our analysis follows four key steps. First, for all locations where weekly or monthly all-cause mortality has been reported since the start of the pandemic, we estimate how much mortality increased compared to the expected death rate. In other words, we estimate excess mortality in all locations with sufficient data. Second, based on a range of studies and consideration of other evidence, we estimate the fraction of excess mortality that is from total COVID-19 deaths as opposed to the five other drivers that influence excess mortality. Third, we build a statistical model that predicts the weekly ratio of total COVID-19 deaths to reported COVID-19 deaths based on covariates and spatial effects. Fourth, we use this statistical relationship to predict the ratio of total to reported COVID-19 deaths in places without data on total COVID-19 deaths and then multiply the reported COVID-19 deaths by this ratio to generate estimates of total COVID-19 deaths for all locations.
**Figure 1.** Reported daily COVID-19 cases

![Graph showing reported daily COVID-19 cases from February 20 to April 21.](image)

**Table 1.** Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>212,025</td>
<td>1</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>175,727</td>
<td>2</td>
</tr>
<tr>
<td>Stroke</td>
<td>126,014</td>
<td>3</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>63,089</td>
<td>4</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>47,946</td>
<td>5</td>
</tr>
<tr>
<td>Tracheal, bronchus, and lung cancer</td>
<td>39,282</td>
<td>6</td>
</tr>
<tr>
<td>Neonatal disorders</td>
<td>36,201</td>
<td>7</td>
</tr>
<tr>
<td>Alzheimer’s disease and other dementias</td>
<td>31,217</td>
<td>8</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>29,830</td>
<td>9</td>
</tr>
<tr>
<td>Diarrheal diseases</td>
<td>29,509</td>
<td>10</td>
</tr>
</tbody>
</table>
Figure 2. Smoothed trend estimate of reported daily COVID-19 deaths (blue) and total daily COVID-19 deaths (orange).
Figure 3. Daily COVID-19 death rate per 1 million on May 10, 2021

Figure 4. Cumulative COVID-19 deaths per 100,000 on May 10, 2021
Figure 5. Estimated percent of the population infected with COVID-19 on May 10, 2021

Figure 6. Mean effective R on April 29, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.
Figure 7. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model.

*Due to measurement errors in cases and testing rates, the infection to detection rate (IDR) can exceed 100% at particular points in time.*
Figure 8. Estimated percent of circulating SARS-CoV-2 for 3 primary variants on May 10, 2021.

A. Estimated percent B.1.1.7 variant

B. Estimated percent B.1.351 or B.1.617 variant

C. Estimated percent P.1 or P.3 variant
**Figure 9.** Infection fatality ratio on May 10, 2021. This is estimated as the ratio of COVID-19 deaths to infections based on the SEIR disease transmission model.

**Critical drivers**

**Figure 10.** Trend in mobility as measured through smartphone app use compared to January 2020 baseline

**Figure 11.** Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on May 10, 2021
**Figure 12.** Trend in the proportion of the population reporting always wearing a mask when leaving home

**Figure 13.** Proportion of the population reporting always wearing a mask when leaving home on May 10, 2021
**Figure 14.** Trend in COVID-19 diagnostic tests per 100,000 people

**Figure 15.** COVID-19 diagnostic tests per 100,000 people on May 03, 2021
Figure 16. Increase in the risk of death due to pneumonia on February 1 2020 compared to August 1 2020.
Table 3. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website (http://www.healthdata.org/node/8584).

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Efficacy at preventing disease: D614G &amp; B.1.1.7</th>
<th>Efficacy at preventing infection: D614G &amp; B.1.1.7</th>
<th>Efficacy at preventing disease: B.1.351 &amp; P.1</th>
<th>Efficacy at preventing infection: B.1.351 &amp; P.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>75%</td>
<td>52%</td>
<td>10%</td>
<td>6%</td>
</tr>
<tr>
<td>CoronaVac</td>
<td>50%</td>
<td>43%</td>
<td>38%</td>
<td>25%</td>
</tr>
<tr>
<td>Janssen</td>
<td>72%</td>
<td>64%</td>
<td>42%</td>
<td>42%</td>
</tr>
<tr>
<td>Moderna</td>
<td>94%</td>
<td>85%</td>
<td>72%</td>
<td>47%</td>
</tr>
<tr>
<td>Novavax</td>
<td>89%</td>
<td>77%</td>
<td>49%</td>
<td>32%</td>
</tr>
<tr>
<td>Pfizer/BioNTech</td>
<td>91%</td>
<td>86%</td>
<td>69%</td>
<td>45%</td>
</tr>
<tr>
<td>Sinopharm</td>
<td>73%</td>
<td>63%</td>
<td>56%</td>
<td>36%</td>
</tr>
<tr>
<td>Sputnik-V</td>
<td>92%</td>
<td>80%</td>
<td>70%</td>
<td>45%</td>
</tr>
<tr>
<td>Tianjin</td>
<td>66%</td>
<td>57%</td>
<td>50%</td>
<td>32%</td>
</tr>
<tr>
<td>CanSino</td>
<td>Other vaccines</td>
<td>Other vaccines (mRNA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>75%</td>
<td>65%</td>
<td>57%</td>
<td>37%</td>
</tr>
<tr>
<td>CoronaVac</td>
<td>95%</td>
<td>83%</td>
<td>72%</td>
<td>47%</td>
</tr>
</tbody>
</table>
**Figure 17.** Trend in the estimated proportion of the adult (18+) population that have been vaccinated or is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).

**Figure 18.** This figure shows the estimated proportion of the adult (18+) population that has been vaccinated or is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).
**Figure 19.** The number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.
Projections and scenarios

We produce three scenarios when projecting COVID-19. The reference scenario is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the UK.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The worse scenario modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P1 begin to spread within 3 weeks in adjacent locations that do not already have B.1.351 or P1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The universal masks scenario makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.
**Figure 20.** Cumulative COVID-19 deaths until September 01, 2021 for three scenarios

**Figure 21.** Daily COVID-19 deaths until September 01, 2021 for three scenarios,
Figure 22. Daily COVID-19 infections until September 01, 2021 for three scenarios.
More information

Data sources:

Mask use data sources include Premise; Facebook Global Symptom Survey (This research is based on survey results from University of Maryland Social Data Science Center) and the Facebook United States Symptom Survey (in collaboration with Carnegie Mellon University); Kaiser Family Foundation; YouGov COVID-19 Behaviour Tracker survey.

Vaccine hesitancy data are from the COVID-19 Beliefs, Behaviors, and Norms Study, a survey conducted on Facebook by the Massachusetts Institute of Technology (https://covidsurvey.mit.edu/).

Vaccine hesitancy data are from the Facebook Global Symptom Survey (This research is based on survey results from University of Maryland Social Data Science Center), the Facebook United States Symptom Survey (in collaboration with Carnegie Mellon University), and from the Facebook COVID-19 Beliefs, Behaviors, and Norms Study conducted by the Massachusetts Institute of Technology.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model FAQ page.

A note of thanks:

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.